EGFR and head and neck squamous cell carcinoma: Cetuximab-based chemotherapy is one of the most widely used treatments for HNSCC, a monoclonal antibody that targets the epidermal growth factor receptor (EGFR), a receptor tyrosine kinase (RTK) within the HER/ErbB family, which includes HER2–4 [13,14].